Lifei Xiaoji Wan in Treatment of Advanced NSCLC

Launched by HENAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE · May 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Lifei Xiaoji Wan for people with advanced non-small cell lung cancer (NSCLC). The goal is to see how well this treatment works and to gather strong evidence about its benefits. The trial is currently looking for participants who are between 18 and 80 years old, have a confirmed diagnosis of NSCLC, and their cancer is at an advanced stage (either stage III or IV). To join, participants should expect to live for at least three more months.

If you or a loved one has advanced NSCLC, this trial might be an option. Participants will receive the study treatment and will help researchers understand how effective it is. However, people who have early-stage lung cancer, serious problems with their heart or other vital organs, or mental health issues that prevent them from completing the study cannot participate. This study aims to provide valuable information for future cancer treatments, and participating could contribute to advancements in care for others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical diagnosis of NSCLC.
• • 2. The tumor stage (TNM) stage is from III to IV.
• • 3. 18-80 years old.
• • 4. The expected survival period is\> 3 months.
• Exclusion Criteria:
• • 1. Early-stage patients with prior surgery and no recurrence.
• • 2. Patients with serious dysfunction of the heart, liver, heart, kidney, and other important organs.
• • 3. Mental illness and other patients were unable to complete the study.